To test the effect of CD4+ Th2 cell immunity in late-stage breast cancer, we used a cell line derived from a MMTV-PyMttg mouse mammary tumor (the PyMt cell line) to establish mammary tumors in mice that represent late-stage breast cancer (11, 21, 22). The gene discussed is CD4; the disease is breast carcinoma.